SMPD1 and myeloid sarcoma: This model also provides a framework for incorporating the effects of medication in the treatment of MS, e.g., fingolimod inhibits aSMase and ceramide [80], including ceramide-induced emergent obesity in MS [150], and, like butyrate, increases gangliosides via HDAC inhibitory effects [85].